The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...
AIM ImmunoTech has announced encouraging data from the ongoing Phase II trial of its Ampligen (rintatolimod) drug plus AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer subjects with ...
Gilead Sciences Inc. (NASDAQ: GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results